|
CDER Patient-Focused Drug Development
 FDA Holds Two FDA-led PFDD Meetings
Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder
- On October 6th, 2020, FDA held a public meeting on PFDD for Stimulant Use Disorder to obtain input from individuals with stimulant use disorder and other stakeholders on the impact of stimulant use disorder and views on treatment goals and approaches.
- The meeting materials, including the agenda, slides, transcript, and recording are now available on the meeting webpage.
- In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket.
- The docket closes on December 7, 2020. Please click here to respond to the questions listed in the public docket.
Public Meeting on Patient-Focused Drug Development for Systemic Sclerosis
- On October 13th, 2020, FDA held a public meeting on PFDD for Systemic Sclerosis to hear perspectives from individuals with systemic sclerosis on the health effects and daily impacts of their systemic sclerosis, treatment goals, and decision factors considered when seeking out or selecting a treatment.
- The meeting materials, including the agenda, slides, transcript, and recording are now available on the meeting webpage.
- In addition to providing input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket.
- The docket closes on December 15, 2020. Please click here to respond to the questions listed in the public docket.
|
|
|
To contact FDA's CDER Patient-Focused Drug Development Program Staff, please email patientfocused@fda.hhs.gov.
If this message was forwarded to you and you would like to subscribe to this free email subscription service, please visit our CDER PFDD Homepage and click the button "Subscribe to Email Updates" at the top of the page.
|
|
|
|
